KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

Andrew Dunn

Senior Biopharma Correspondent

The CEO of KalVista Pharmaceuticals described the behind-the-scenes discussions with FDA reviewers as “appropriate,” “thorough” and “productive” in what led to

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

KalVista CEO says FDA re­view pro­ceed­ed nor­mal­ly, was un­aware of Makary's re­jec­tion ask

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases